Indirect comparison of zanubrutinib versus ibrutinib for treatment of relapsed MCL.
Home / Resource Library / An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma